Twitter | Search | |
Allergan plc
Bold for Life
488
Tweets
126
Following
26,859
Followers
Tweets
Allergan plc retweeted
Brent Saunders Aug 19
Proud to join my fellow CEOs in committing to lead our companies for the benefit of all stakeholders: customers, employees, suppliers, communities and shareholders
Reply Retweet Like
Allergan plc retweeted
IFFGD Aug 13
Last year IFFGD partnered w/ to spread awareness about . A diagnosis of diabetic gastroparesis often leaves patients w/ more questions than answers. Follow the link to learn more
Reply Retweet Like
Allergan plc Aug 15
Resources for patients & physicians about the withdrawal of BIOCELL® textured breast implants and tissue expanders are available at
Reply Retweet Like
Allergan plc Aug 6
Today, Allergan announced Q2 2019 financial results. Read more here:
Reply Retweet Like
Allergan plc Jul 30
At , we are excited to continue our legacy in retina and eye care by presenting data on our investigational anti-VEGF therapy for patients with nAMD.
Reply Retweet Like
Allergan plc Jul 27
We are making a donation to the ASRS Foundation for every participant who takes our quiz at Booth 519! Stop by to support the ongoing research in the field of retinal diseases.
Reply Retweet Like
Allergan plc Jul 26
Allergan is at the Headache Update 2019 conference connecting with colleagues and advancing scientific exchange. is proud to showcase its commitment to the pursuit of with 9 migraine-related abstracts.
Reply Retweet Like
Allergan plc Jul 26
Allergan is looking forward to discussing DARPin molecules—an investigational binding alternative that is not derived from antibodies. Visit us at Booth 519 during to see them in action.
Reply Retweet Like
Allergan plc Jul 25
Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders. For more information: For U.S. based questions call 1-800-678-1605 or IR-Medcom@allergan.com. All other countries, please see:
Reply Retweet Like
Allergan plc Jul 24
Replying to @JoanieMarie16
Hi Joanie, If you follow us we can exchange direct messages so we can learn more information. Once you do, we will be in touch.
Reply Retweet Like
Allergan plc Jul 19
is the second leading cause of blindness globally.
Reply Retweet Like
Allergan plc Jul 18
In 2018, nearly 130 million people were living with globally. This number is expected to rise to an estimated 148 million by 2023.
Reply Retweet Like
Allergan plc Jul 17
Hear from David Nicholson, EVP & Chief R&D Officer on what the filing of our New Drug Application (NDA) for Bimatoprost Sustained Release (SR) could mean for patients with , a leading cause of blindness.
Reply Retweet Like
Allergan plc Jul 17
The Food and Drug Administration (FDA) has accepted the filing of our New Drug Application (NDA) for Bimatoprost Sustained-Release (SR), for the reduction of IOP in patients with open-angle or ocular hypertension.
Reply Retweet Like
Allergan plc Jul 14
That’s a wrap ! Thanks to for the opportunity to connect with the industry's leading minds. Together, we can drive progress and advance the pursuit of .
Reply Retweet Like
Allergan plc Jul 13
We're onsite at with Dr. Joel Trugman. Watch the below video for more info on data across our migraine franchise.
Reply Retweet Like
Allergan plc Jul 11
We're thrilled to share the latest in migraine innovation at the 2019 annual meeting with 29 presentations. Learn more about our abstracts here and stay tuned for updates:
Reply Retweet Like
Allergan plc Jul 1
Joel from is just one member of the biopharmaceutical industry researching innovative treatments for migraine patients to reduce the length and frequency of migraine attacks.
Reply Retweet Like
Allergan plc Jun 25
Allergan has entered into a definitive agreement to combine with AbbVie in a transformative move for both companies. Read more in the press release.
Reply Retweet Like
Allergan plc Jun 24
Introducing the newest addition to the Allergan portfolio: CoolTone by CoolSculpting, recently FDA-cleared! Be one of the first to learn more:
Reply Retweet Like